Icosapent Ethyl
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Icosapent Ethyl: From Hypertriglyceridaemia to Myocardial Infarction
One-Sentence Summary
Icosapent ethyl (Vascepa®) is a highly purified EPA ethyl ester established internationally for lowering triglycerides and reducing cardiovascular events in high-risk patients. Among 10 TxGNN-predicted indications, Myocardial Infarction stands out with the strongest supporting evidence, backed by 8 clinical trials (including the pivotal REDUCE-IT programme) and 20 publications, while the other 9 predictions currently have little to no drug-specific evidence.
Note: This evidence pack does not contain original-indication or ARTG licence data for icosapent ethyl (0 ARTG entries — the drug is not currently marketed in Australia). “Hypertriglyceridaemia” above reflects the drug’s well-established overseas (e.g. US FDA) approved use, not TFDA/TGA-sourced data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack — the drug is not TGA-registered. Overseas regulators (US FDA) approve icosapent ethyl for severe hypertriglyceridaemia and cardiovascular risk reduction. |
| Predicted New Indication | Myocardial Infarction |
| TxGNN Prediction Score | 98.60% (rank 13,820 of all drug-disease pairs; selected as the leading candidate among the 10 predictions supplied due to its evidence strength, rather than the highest raw score) |
| Evidence Level | L1 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed DrugBank mechanism-of-action text was not returned for this drug (data gap). Based on well-established pharmacology, icosapent ethyl is a highly purified eicosapentaenoic acid (EPA) ethyl ester. Its cardiovascular benefit is thought to arise from multiple complementary mechanisms: triglyceride lowering, anti-inflammatory effects, plaque stabilisation, and mild antiplatelet activity.
Myocardial infarction sits within the same cardiovascular risk continuum that the drug’s approved triglyceride-lowering use already targets — patients treated for hypertriglyceridaemia are, by definition, at elevated atherosclerotic cardiovascular risk. The TxGNN prediction is therefore mechanistically coherent rather than a novel biological leap.
This is also the only one of the 10 predicted indications with direct, drug-specific randomised controlled trial evidence: the REDUCE-IT trial (PMID 30415628) demonstrated a significant reduction in the composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, coronary revascularisation, or unstable angina in statin-treated patients with elevated triglycerides — and multiple REDUCE-IT post-hoc analyses specifically examine MI outcomes and subtypes.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00231738 | Phase 4 | Completed | 18,000 | JELIS: highly purified EPA + statin reduced major cardiovascular events vs statin alone in hypercholesterolaemic Japanese patients |
| NCT04505098 | Phase 4 | Terminated | 39,600 | MITIGATE: pragmatic real-world RCT of IPE pre-treatment in high-CV-risk adults, targeting viral URI-related morbidity/mortality; terminated |
| NCT05271591 | N/A | Completed | 200 | REDUCE-IT Canada SA: cross-sectional analysis of South-Asian patients meeting the Health Canada-approved IPE indication |
| NCT04460651 | Phase 3 | Completed | 4,093 | PREPARE-IT: pure IPE evaluated for COVID-19 prevention/treatment — not MI-specific |
| NCT00069784 | Phase 3 | Completed | 12,537 | ORIGIN: 2×2 factorial trial; omega-3 fatty acids vs placebo for CV mortality in IFG/IGT/early T2DM — omega-3 was a secondary arm |
| NCT00692718 | Phase 4 | Unknown | 160 | N-3 fatty acids for atrial fibrillation prevention after acute MI/heart failure — AF was the primary endpoint, not MI |
| NCT00771914 | Phase 1/2 | Completed | 27 | Small pharmacodynamic study of omega-3 fatty acids on aspirin resistance |
| NCT06280976 | Phase 4 | Withdrawn | 0 | ART-CAP: coronary plaque assessment study; withdrawn before enrolment, no data available |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40982548 | 2025 | RCT (post-hoc) | Eur J Prev Cardiol | REDUCE-IT sub-analysis: IPE benefit consistent across different MI types and infarct sizes |
| 35483753 | 2022 | RCT (post-hoc) | J Am Coll Cardiol | REDUCE-IT sub-analysis: IPE reduced CV events/mortality specifically in patients with prior MI |
| 30415628 | 2019 | RCT | N Engl J Med | REDUCE-IT primary results: IPE reduced ischaemic events in statin-treated patients with elevated triglycerides |
| 34710343 | 2021 | RCT (post-hoc) | Circulation | REDUCE-IT CABG: IPE reduced ischaemic events in patients with prior coronary bypass surgery |
| 38530686 | 2024 | RCT (post-hoc) | J Am Coll Cardiol | Lipoprotein(a) levels and cardiovascular risk reduction with IPE |
| 36802845 | 2023 | RCT (post-hoc) | J Am Heart Assoc | REDUCE-IT sub-analysis: CV benefit of IPE with/without atrial fibrillation (increased AF hospitalisation noted) |
| 38035037 | 2023 | RCT | Eur Heart J Open | REDUCE-IT MetSyn: IPE effectiveness in patients with metabolic syndrome without diabetes |
| 31567003 | 2019 | Meta-Analysis | J Am Heart Assoc | Meta-analysis of 13 RCTs (127,477 patients): marine omega-3 supplementation and CVD/MI risk |
| 40752806 | 2025 | Cohort | Int J Cardiol | CALLINICUS-Hellas registry: IPE eligibility 1–3 months post-ACS and risk of MI re-infarction |
| 28294373 | 2017 | Trial design paper | Clin Cardiol | Rationale and design of the REDUCE-IT trial |
Australia Market Information
Icosapent ethyl currently has no ARTG entries and is not marketed in Australia. No local product information is available at this time.
Safety Considerations
No key warnings, contraindications, or drug interaction data were returned for this drug (DrugBank DDI query: not found). As icosapent ethyl is not TGA-registered, there is no Australian Product Information to reference. Prescribers should consult overseas regulatory labelling (e.g. the US FDA-approved Vascepa label) for interim safety guidance until formal TGA documentation is available.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale:
- The myocardial infarction indication is supported by Phase 3/4 RCT evidence, including the pivotal REDUCE-IT trial and multiple confirmatory post-hoc analyses, giving it L1 evidence strength. However, the drug is not TGA-registered in Australia and safety documentation (warnings, contraindications, DDI) is entirely unavailable, which blocks progression past initial safety screening.
To proceed, the following is needed:
- TGA/TFDA-sourced Product Information (warnings, contraindications) — currently a blocking data gap (DG001)
- Confirmed DrugBank mechanism-of-action data (DG002)
- A formal DDI database query (current query returned “not found”)
- An assessment of the Australian registration pathway, since there are currently 0 ARTG entries
- The other 9 lower-ranked predictions (e.g. hemoglobinopathy, beta-thalassaemia, rheumatoid arthritis) should be treated separately — they currently have no drug-specific clinical or literature evidence and remain at Hold/L4-L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.